Therapeutic Asset Ratings

132 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
art6043 Metastatic Solid Tumor	Artios Pharma Ltd	P1/2	CC (41)
Clofarabine Metastatic Solid Tumor	Triumvira Immunologics, Inc.	P1/2	CC (41)
cn202 Metastatic Solid Tumor	Curon Biopharmaceutical (Australia) Co Pty Ltd	P1/2	CC (41)
ds-3939a Metastatic Solid Tumor	Daiichi Sankyo	P1/2	CC (41)
Eribulin Metastatic Solid Tumor	GI Innovation, Inc.	P1/2	CC (41)
Fianlimab Metastatic Solid Tumor	University Medical Center Groningen	P1/2	CC (41)
Fmc-376 Metastatic Solid Tumor	Frontier Medicines Corporation	P1/2	CC (41)
gi-101a Metastatic Solid Tumor	GI Innovation, Inc.	P1/2	CC (41)
gi-102 Metastatic Solid Tumor	GI Innovation, Inc.	P1/2	CC (41)
gi-108 Metastatic Solid Tumor	GI Innovation, Inc.	P1/2	CC (41)
human T-lymphocyte activation antigen CD80 (activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CD80) extracellular domain containing fragment (1-208 in the current sequence) fused via peptide linker <sup>209</sup>GSGGGGSGGGGSGGGGS<sup>225</sup> to an Fc fragment of human immunoglobulin G4 (226-454) [Homo sapiens IGHG4*01, hinge ins<sup>226</sup>>A, S<sup>236</sup>>P (226-238), CH2 F<sup>242</sup>>A, L<sup>243</sup>>A, T<sup>258</sup>>Q (239-348), CH3 M<sup>436</sup>>L (349-453), CHS K<sup>455</sup>>del (454)] fused via peptide/ linker <sup>455</sup>GGGGS<sup>459</sup> to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) (1-133, 460-592 in the current sequence), variant (R<sup>38</sup>>A<sup>497</sup>, F<sup>42</sup>>A<sup>501</sup>), dimer (234-234', 237-237')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa Metastatic Solid Tumor	GI Innovation, Inc.	P1/2	CC (41)
(-)-Hydroxyurea methylacylfulvene Metastatic Solid Tumor	Lantern Pharma Inc.	P1/2	CC (41)
Idp-001 Metastatic Solid Tumor	InduPro, Inc.	P1/2	CC (41)
Inno-206 Metastatic Solid Tumor	GI Innovation, Inc.	P1/2	CC (41)
ip-001 Metastatic Solid Tumor	Immunophotonics, Inc.	P1/2	CC (41)
Ipilimumab Metastatic Solid Tumor	Lantern Pharma Inc.	P1/2	CC (41)
ipn01203 Metastatic Solid Tumor	Ipsen	P1/2	CC (41)
ipn60300 Metastatic Solid Tumor	Ipsen	P1/2	CC (41)
Itraconazole Metastatic Solid Tumor	Nuvalent Inc.	P1/2	CC (41)
Jbi-802 Metastatic Solid Tumor	Jubilant Therapeutics Inc.	P1/2	CC (41)
LENVATINIB Metastatic Solid Tumor	GI Innovation, Inc.	P1/2	CC (41)
MIDAZOLAM Metastatic Solid Tumor	Nuvalent Inc.	P1/2	CC (41)
Neladalkib Metastatic Solid Tumor	Nuvalent Inc.	P1/2	CC (41)
REPAGLINIDE Metastatic Solid Tumor	Nuvalent Inc.	P1/2	CC (41)
Rezatapopt Metastatic Solid Tumor	PMV Pharmaceuticals, Inc	P1/2	CC (41)

Showing 26 to 50 of 132 assets

PreviousPage 2 of 6Next